Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,751
Out of 5,150 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $18.62 | -8.70% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $39.61 | -6.59% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $62.33 | +34.77% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,003.57 | -47.69% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $5.59 | +132.56% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $13.42 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $120.28 | -22.68% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $24.12 | +99.00% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.76 | +1,377.27% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.60 | +24,755.01% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $11.69 | +567.24% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $125.96 | -38.08% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $32.91 | -45.31% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $208.95 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $188.69 | -7.26% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $236.19 | -72.06% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $18.62
Upside: -8.70%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $39.61
Upside: -6.59%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $62.33
Upside: +34.77%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,003.57
Upside: -47.69%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $5.59
Upside: +132.56%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $13.42
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $120.28
Upside: -22.68%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $24.12
Upside: +99.00%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.76
Upside: +1,377.27%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.60
Upside: +24,755.01%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $11.69
Upside: +567.24%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $125.96
Upside: -38.08%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $32.91
Upside: -45.31%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $208.95
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $188.69
Upside: -7.26%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $236.19
Upside: -72.06%